Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy
Gaigai Wei, Huiling Zhang, Haiping Zhao, et al.
Cancer Letters (2021) Vol. 511, pp. 68-76
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Clinical cancer immunotherapy: Current progress and prospects
Chenglong Liu, Mengxuan Yang, Daizhou Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 144
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives
Sawsan Sudqi Said, Wisam Nabeel Ibrahim
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1143-1143
Open Access | Times Cited: 50
The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells
Qingyu Lin, Xingwen Wang, Ying Hu
Cancer Letters (2023) Vol. 569, pp. 216318-216318
Open Access | Times Cited: 50
Crosstalk between metabolism and cell death in tumorigenesis
Shichao Yang, Caden Hu, Xiaomei Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 24
Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials
Dhananjay Yadav, Minseok Kwak, Pallavi Chauhan, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 909-922
Closed Access | Times Cited: 45
Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers
Fukang Shi, Xing Huang, Zhengtao Hong, et al.
Cancer Letters (2023) Vol. 562, pp. 216167-216167
Open Access | Times Cited: 21
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
L. Pabst, Sébastien Lopes, Basil Bertrand, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7577-7577
Open Access | Times Cited: 20
Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy
Wenpan Li, Yanhao Jiang, Jianqin Lu
International Journal of Pharmaceutics (2023) Vol. 634, pp. 122655-122655
Open Access | Times Cited: 18
Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies
Yuanyuan Guo, Fengyuan Gao, Adeel Ahmed, et al.
Journal of Materials Chemistry B (2023) Vol. 11, Iss. 36, pp. 8586-8604
Closed Access | Times Cited: 18
Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)
Haihong Jiang, Qinlu Zhang
Oncology Letters (2024) Vol. 27, Iss. 2
Open Access | Times Cited: 7
Traditional medicine herbs as natural product matrices in cancer chemoprevention: A trans pharmacological perspective (scoping review)
Mangathayaru Kalachaveedu, Reshma Senthil, Sowndarya Azhagiyamanavalan, et al.
Phytotherapy Research (2023) Vol. 37, Iss. 4, pp. 1539-1573
Closed Access | Times Cited: 15
Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy
Miaomiao Chen, Si-Liang Wang
International Immunopharmacology (2024) Vol. 130, pp. 111717-111717
Closed Access | Times Cited: 5
A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody
Tongcheng Dai, Hao Sun, Tyler Liban, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Harnessing Peptide-based Nanotherapeutics: Pioneering Melanoma Management from Diagnosis to Theranostics
Shalini Shukla, Pooja Khairnar, Aachal Hedaoo, et al.
Journal of Drug Delivery Science and Technology (2025), pp. 106811-106811
Closed Access
Pathogenic mitochondrial dysfunction and metabolic abnormalities
Walter H. Moos, Douglas V. Faller, Ioannis P. Glavas, et al.
Biochemical Pharmacology (2021) Vol. 193, pp. 114809-114809
Open Access | Times Cited: 30
Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy
Yuting Jia, Bin Guo, Wenbin Zhang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 10
Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia
Marta Tenuta, Carla Pandozzi, Francesca Sciarra, et al.
Cancers (2023) Vol. 15, Iss. 14, pp. 3592-3592
Open Access | Times Cited: 10
BTG2 and SerpinB5, a novel gene pair to evaluate the prognosis of lung adenocarcinoma
Wanting Yang, Chunli Wei, Jingliang Cheng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Profiling of Tumor-Infiltrating Immune Cells and Their Impact on Survival in Glioblastoma Patients Undergoing Immunotherapy with Dendritic Cells
Nataly Peres, Guilherme Lepski, Carla S. Fogolin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5275-5275
Open Access | Times Cited: 3
Injectable shear-thinning polylysine hydrogels for localized immunotherapy of gastric cancer through repolarization of tumor-associated macrophages
Yang Yan, Yang Yang, Meili Chen, et al.
Biomaterials Science (2021) Vol. 9, Iss. 19, pp. 6597-6608
Closed Access | Times Cited: 22
Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent
Levon M. Khachigian
Cancer Letters (2021) Vol. 522, pp. 57-62
Closed Access | Times Cited: 18
Expanding individualized therapeutic options via genoproteomics
Dongdong Zhan, Pengfei Zheng, Beibei Zhao, et al.
Cancer Letters (2023) Vol. 560, pp. 216123-216123
Open Access | Times Cited: 7
Construction of a TAN-associated risk score model with integrated multi-omics data analysis and clinical validation in gastric cancer
Zhangdi Xu, Lan Zhang, Xiaping Wang, et al.
Life Sciences (2024) Vol. 349, pp. 122731-122731
Closed Access | Times Cited: 2
Pyroptosis-Related lncRNA Prognostic Model for Renal Cancer Contributes to Immunodiagnosis and Immunotherapy
Xuan Zhou, Liangyu Yao, Xiang Zhou, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 11
Identification of an Endoplasmic Reticulum Stress-Related Gene Signature to Evaluate the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma
Dingli Song, Zhenyu Zhou, Dai Zhang, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top